United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $529.59, for a total value of $5,031,105.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $21,455,279.67. This represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $3.35 during mid-day trading on Thursday, reaching $527.00. 504,858 shares of the company’s stock were exchanged, compared to its average volume of 434,849. The firm has a market capitalization of $23.10 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 1.94 and a beta of 0.84. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The firm has a 50-day moving average price of $488.85 and a two-hundred day moving average price of $465.99.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.19 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on UTHR shares. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Royal Bank Of Canada increased their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. TD Cowen upped their price target on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $548.09.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Torren Management LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in United Therapeutics in the 4th quarter worth about $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.